美股市場個股詳情

ONCT Oncternal Therapeutics

添加自選

8.6350
+0.0800+0.94%

收盤價 05/09 16:00 (美東)

9.0500
+0.4150+4.81%

盤後 17:55 (美東)

2555.65萬總市值-642市盈率TTM

Oncternal Therapeutics股票討論區

登錄發表評論

Trytosaveabit

04/18 21:01

Update

$Oncternal Therapeutics(ONCT.US)$ Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Trytosaveabit

01/08 22:16

Update

$Oncternal Therapeutics(ONCT.US)$ Oncternal Therapeutics Enrolls Patients In Third Dosing Cohort Of Phase 1/2 Study Of ONCT-534

Trytosaveabit

2023/10/26 21:05

News

$Oncternal Therapeutics(ONCT.US)$ Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
5 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE

Moomoo AI

2023/10/25 21:06

Dr. Smith's advisory role will help shape the clinical strategy for ONCT-534. Her expectation is that the drug could deal with escape mechanisms of a specific prostate cancer, boosting its prospective efficiency and market validity.